概览
转眼瞬间已九载，凝神常思向十年。2018年，DIA中国年会将迎来10周岁。
十年前，当中国尚未全面参与国际多中心临床试验时，DIA来到中国，在北京主办召开了以“从‘平坦世界’的视角看药物研发：创新、法规和全球化”为主题的第一届中国年会。自2009年首届年会以来，DIA在中国的十年，是见证中国医药风雨兼程地从传统制药走向自主创新的十年，是中国医药健康产业蓬勃发展的十年，也是见证中国药监改革快速发展硕果累累的十年。刚刚过去的两年中，国家食品药品监督管理局（CFDA）已经展示了前所未有的决心，推出了一系列措施深化制度改革，确保公众用药的有效性与安全性。
2017年5月21日，在上海国际会议中心举办的第九届DIA中国年会上，CFDA--DIA联合举办的有关ICH的研讨会向世界传递了来自中国的坚定的声音。2017年6月，CFDA正式加入ICH标志了中国药监历史上的一个重要的里程碑。
2018年，第十届DIA中国年会，DIA亚洲最大的跨学科盛会，您是否想参加？您是否想在中国生命科学创新如此激动人心的时刻为非凡事件贡献一份力量？
第十届 DIA 中国年会设有壁报展览。这是一个交流知识和经验，应用新技术和新方法的良机。
项目委员会
-
Pei HU Director, Phase I Unit, Clinical Pharmacological Research Center
Peking Union Medical College, China -
Bin Xue Director-General
China Center for Food and Drug International Exchange, NMPA, China -
Xiaojun (Wendy) Yan, MD, MBA Senior Vice President, Chief Regulatory Officer
BeiGene (Beijing) Co., Ltd., China -
Irene Deng Head of Regulatory Affairs, China
Sanofi, China -
Jin Cui Program Officer
China Center for Food and Drug International Exchange , China -
George LIU Head of Early Development and Scientific Operation
Harbour Biomed, China -
Zhiqiang Ning Vice President, Research & Clinical Development
Shenzhen Chipscreen Biosciences, Ltd., China -
Jessica Liu, MD VP, Head of Merges and Acquisition Management Department
Tigermed Consulting Co., Ltd, China -
Sunny Zhu Chief Medical Officer, Infectious Diseases
Everest Medicines, China -
Hannah Chen, MD Consultant
Beijing XiaoTongMingDa Technology Ltd., China -
Paul Dai, MD Head of Clinical Operations
TDC, Asia, Takeda, China -
Reako Ren Head of SMO Services
WuXi AppTec, China -
Connie Dai Vice President, Strategy Innovation and Decision Science
HLT, China -
Hualong Sun General manager
Meta Clinical Technical Co. Ltd, China -
Charles Yan Vice President, Head of Clinical Data Science Center
Jiangsu Hengrui, China -
Melly Lin CMC Regulatory Policy Lead, Pharma Technical Regulatory
F. Hoffmann-La Roche Ltd, Switzerland -
Joe Zhang Co-founder and CEO
BJ Bioscience Inc., China -
Xiangyang Zhu CEO
Shanghai Huaota Biopharma Co., Ltd, China -
Li L Wang Senior Vice President, Lilly China Drug Development and Medical Affairs Center
Eli Lily & Company, China -
Xiaoling Wang Clinical Documentation
Clinical Science Operation, Sanofi R&D China, China -
Xue TANG Drug Safety Unit Regional Head (DRH),
APAC Pfizer, China -
Dayao ZHAO, MD, PhD Former Vice President and Lead, China Drug Development
Pfizer, China -
Jane Y. Cai, PhD Former Managing Director
DIA China, China -
Tony Guo Executive Director, Head of Biometrics China
BeiGene, China -
Tong Guo CEO
GEM Flower Pharma Tech, China -
Amber Wang Vice President, Regulatory Affairs & QA
SmithNephew, China -
Ruyi He, MD Chief Scientist
Center for Drug Evaluation, CFDA, United States -
Jingsong Wang, MD Founder, Chairman, and Chief Executive Officer
Harbour BioMed, China -
Shun Lu Director, Center for Clinical Medicine of Lung Cancer, Shanghai Chest Hospital,
Shanghai Jiaotong University, China -
Xianglin Zhang President
Shenyang Pharmaceutical University, China -
Carol Zhu, MBA Vice President, Portfolio and Project Management
JW Therapeutics, China -
Ron Fitzmartin, PhD, MBA Senior Informatics Advisor, Office of Regulatory Operations, CBER
FDA, United States -
Murray M. Lumpkin, DrMed, MD, MSc Deputy Director, Integrated Development, Lead for Global Reg Systems Initiative
Bill and Melinda Gates Foundation, United States -
Kenneth Getz, MBA Tufts Center for the Study of Drug Development
Center For the Study of Drug Development, United States -
Sandy Milligan, JD, MD Board of Director Member, Gossamer Bio; Principal
Innovex Strategies, United States -
Ling Su, PhD Research Fellow
Shenyang Pharmaceutical University, Yeehong Business School, China